COPD Drugs Market in China 2016-2020

COPD drugs market forecast in China

According to the COPD drugs industry analysis, the chronic obstructive pulmonary disease (COPD) drugs market in China is envisaged to witness impressive growth and will post a CAGR of more than 15% over the forecast period. With the increasing population of smokers in the country, the market for COPD drugs in China will have a positive outlook in the coming years. Smoking leads to the damage of airways, air sacs, and the lining of the lungs, and triggers COPD flare-ups. China is the largest producer of tobacco in the world and accounts for nearly 42% of the world’s cigarette production. Also, the WHO has estimated that almost a third of the world’s smoking population is present in China. Moreover, factors like the improving economic conditions of the country have led individuals to smoke more cigarettes annually, which is anticipated to indirectly drive the COPD drugs market during the predicted period.

One of the emerging COPD drugs industry trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs. Moreover, combination therapies reduce COPD-related hospitalizations and result in better treatment outcomes in patients. Therefore, it can be estimated that the increasing use of combinations therapies will increase the patient compliance toward the use of these respiratory drugs, which will, in turn, fuel this market’s growth prospects over the next four years.

COPD drugs market segmentation by drug class in China

• Bronchodilators
• PDE-4 inhibitors
• Steroids
• Combination therapies

The bronchodilators segment is one of the fastest growing segments of the COPD drugs market. Bronchodilators help relax bronchial muscles resulting in normal breathing. These drugs can be categorized into three types, namely beta-sympathomimetic, anticholinergics, and xanthine derivatives.

Competitive landscape and key vendors

Due to the presence of several small and large vendors, the COPD drugs market in China is highly competitive. The competitive environment is expected to intensify with the increase in product extensions, technological innovations, and an increase in the number of mergers and acquisitions.

 Key vendors in this market are 

• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis

Other prominent vendors analyzed in this report are Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan NV, Orion Corporation, Pearl Therapeutics, Prosonix, Teva Pharmaceutical, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the COPD drugs market in China?
• What are the key market trends impacting the growth of the COPD drugs market in China?
• What are the challenges to market growth?
• Who are the key vendors in COPD drugs market in China?
• What are the market opportunities and threats faced by the vendors in the COPD drugs market in China?
• Trending factors influencing the market shares of China.
• What are the key outcomes of the five forces analysis of COPD drugs market in China?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global COPD and Asthma Devices Market - Industry Analysis 2015-2019
• Pulmonary Hypertension - Global Market Research 2015-2019
• Global Nebulizers Market 2016-2020
• Global Pneumatic Nebulizers Market 2016-2020